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Abstract
Background: Oocyte donation has been associated to gestational diabetes, hypertensive disorders, placental
abnormalities, preterm delivery and increased rate of caesarean delivery while simultaneously being characterized
by high rates of primiparity, advanced maternal age and multiple gestation constituting the individual risk of mode
of conception difficult to assess. This study aims to explore obstetrical outcomes among relatively young women
with optimal health status conceiving singletons with donated versus autologous oocytes (via IVF and spontaneously).
Methods: National retrospective cohort case study involving 76 women conceiving with donated oocytes, 150
nulliparous women without infertility conceiving spontaneously and 63 women conceiving after non-donor IVF. Data
on obstetric outcomes were retrieved from the National Birth Medical Register and the medical records of oocyte
recipients from the treating University Hospitals of Sweden. Demographic and logistic regression analysis were
performed to examine the association of mode of conception and obstetric outcomes.
Results: Women conceiving with donated oocytes (OD) had a higher risk of hypertensive disorders [adjusted Odds
Ratio (aOR) 2.84, 95 % CI (1.04–7.81)], oligohydramnios [aOR 12.74, 95 % CI (1.24–130.49)], postpartum hemorrhage [aOR
7.11, 95 % CI (2.02–24.97)] and retained placenta [aOR 6.71, 95 % CI (1.58–28.40)] when compared to women who
conceived spontaneously, after adjusting for relevant covariates. Similar trends, though not statistically significant, were
noted when comparing OD pregnant women to women who had undergone non-donor IVF. Caesarean delivery [aOR
2.95, 95 % CI (1.52–5.71); aOR 5.20, 95 % CI (2.21–12.22)] and induction of labor [aOR 3.00, 95 % CI (1.39–6.44); aOR 2.80,
95 % CI (1.10–7.08)] occurred more frequently in the OD group, compared to the group conceiving spontaneously and
through IVF respectively. No differences in gestational length were noted between the groups. With regard to the
indication of OD treatment, higher intervention was observed in women with diminished ovarian reserve but the risk
for hypertensive disorders did not differ after adjustment.
Conclusion: The selection process of recipients for medically indicated oocyte donation treatment in Sweden seems
to be effective in excluding women with severe comorbidities. Nevertheless, oocyte recipients-despite being relatively
young and of optimal health status- need careful counseling preconceptionally and closer monitoring prenatally for
the development of hypertensive disorders.
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Background
Oocyte donation (OD) is a well-established form of infer-
tility treatment for women with premature ovarian failure,
which may be caused by idiopathic or iatrogenic (after
chemotherapy/ radiation/ surgery) diminished ovarian re-
serve, Turner syndrome, repeated unsuccessful IVF treat-
ments and inheritable genetic maternal disorders [1]. In
some countries, women with natural menopause can also
receive treatment with donated oocytes.
Since the introduction of oocyte donation, there
have been conflicting reports about the possible over-
representation of this group among those presenting
with complications during pregnancy and delivery.
Several studies have suggested that an increase in the
incidence of gestational diabetes [2], hypertensive dis-
orders [3–8], placental abnormalities [9], preterm de-
livery [9] and increased rate of caesarean delivery [9]
may be related to this treatment. According to research
on immunological aspects of OD pregnancies, some
clinical complications may theoretically arise, as the
embryo resulting from oocyte donation is immuno-
logically unrelated to the mother and this difference
might predispose to placental pathology [10, 11]. On
the other side, pregnancies following oocyte donation
are often characterized by high rates of primiparity and
multiple gestation [6, 12], factors that might introduce
a bias when assessing the association between OD and
pregnancy complications.
Sweden first permitted oocyte donation in 2003,
solely on the basis of medical indication; oocyte dona-
tion now represents approximately 2.5 % of the total
IVF and ICSI treatment cycles [13] with a total preg-
nancy and live birth rate per embryo transfer at about
30 %. Reproductive centers in Sweden, i.e. the Univer-
sity clinics that are allowed to perform IVF treatment
with donated oocytes, practice mostly single embryo
transfer (SET) and therefore the multiple pregnancy
rate in IVF settings overall is now 4.8 % of all pregnan-
cies [13]. It should be stressed that in 2010, only 10 %
of oocyte donation cycles in Sweden were performed in
women older than 40 years, which constitutes by far
the lowest rate in Europe [14, 15].
To date, no previous studies have compared the asso-
ciation between oocyte donation and obstetric outcomes
in a national setting. Thus the aim of this study was to
investigate if singleton pregnancies following oocyte do-
nation based on medical indication in a sample of Swed-
ish women with optimal health status in fertile age are
more often associated with adverse obstetric outcomes
compared to (i) naturally conceived pregnancies (in nul-
liparous women without infertility) and (ii) pregnancies
conceived after non donor IVF. Furthermore, we aimed
to study whether outcomes differed depending on the
specific indication leading to treatment.
Methods
Study sample and data collection
The present study is part of the “Swedish multicenter
study on gamete donation”, a cohort study of donors and
recipients of donated gametes receiving treatment at fer-
tility clinics performing donation treatment in Sweden,
at the University Hospitals in Stockholm, Gothenburg,
Uppsala, Umeå, Linköping, Örebro and Malmö. Subfertile
couples are accepted for inclusion on the gamete donation
program after medical and psychological assessment per-
formed at the treating clinics. During the period 2005–
2008, consecutive couples starting donation treatment were
approached regarding participation. The Index group com-
prises of women who later gave birth to one child following
treatment with donated oocytes. Women who did not
speak and/or read Swedish were excluded [16]. Written
and oral information was given and participants signed an
informed consent form allowing the research group to have
access to the medical records.
Two control groups were used in order to assess the
outcome;
a) Nulliparous women (Control group A) with
spontaneously conceived pregnancies, singleton
deliveries and no history of subfertility found in the
medical register. All controls in group A were
matched to the Index group in regard to age in
three categories, ≤29, 30–34, ≥35 years, at a ratio of
2:1. With the exception of the eligibility criteria
according to study design, Control group A was
otherwise selected randomly. Unidentifiable
information on the study subjects of Control group
A was obtained and thus personal informed consent
was not necessary for that group.
b) Heterosexual women (Control group B) undergoing
in vitro fertilization (IVF) treatment with their own
gametes due to couple infertility at the University
hospitals mentioned above. All Swedish speaking
women receiving traditional IVF treatment
concurrently to the Index group were approached
regarding participation on the “Swedish multicentre
study on gamete donation” and constituted the
original control cohort [16]. However solely those
who conceived with singleton pregnancies during
and on the imminent study period were finally
included in Control group B. Age matching was not
performed. The women were given written and oral
information about the study and informed consent
was obtained.
All medical data analyzed were retrieved from the Swedish
Medical Birth Register (MBR), a Swedish population-based
register started in 1973 and held by the Swedish National
Board of Health and Welfare. MBR, which is a validated
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register, includes information beginning with prenatal care
and continuing through the delivery care and neonatal care
[17–19]. Other medical information such as the treatment
indication for the oocyte recipients originates from their
treatment protocol after scrutinization of the medical record
at each center.
The rationale for also including heterosexual women
undergoing IVF as a control group was in order to in-
vestigate if the increased risks for oocyte recipients re-
ported previously are attributable solely to donation. IVF
pregnancies with autologous gametes are nowadays con-
sidered to be hampered by the underlying infertility, the
characteristics of the infertile couple and/or the use of
assisted reproductive techniques (i.e. conventional IVF
or ICSI technique, fresh or frozen-thawed embryos) [20].
Our series include no maternal deaths. However one
fetal intrauterine death in Control group A occurred on
the 29th week of gestation.
Outcome measures
The medical data studied were based on the diagnosis
according to the tenth version of the International
Classification of Diseases (ICD-10) that the woman had
received on the MBR. The following variables referring
to medical practices and complications were studied:
Mode of delivery [subdivided into Non Emergency and
Emergency Caesarean Section, Normal Vaginal Delivery,
Instrumental Delivery (with Vacuum extraction)], Induction
of labor, Pregnancy Induced Hypertension, Preeclampsia,
Eclampsia, HELLP syndrome or Hypertensive disorders of
pregnancy as a whole (including all of the latter), Small for
Gestational Age (SGA), Large for Gestational Age (LGA),
Oligohydramnios, Polyhydramnios, Uterine Inertia, Fetal
distress (either due to non reassuring heart beat on cardio-
tocography or acidemia/acidosis on fetal scalp blood test),
Placenta praevia, Placental abruption, Retained Placenta
with or without bleeding, Hemorrhage after labor, Nitrous
Oxide gas or Epidural Anesthesia, Obstetrical lacerations of
third or fourth grade, Total maternal hospital stay (from
delivery date until hospital discharge). It should be noted
that SGA and LGA were defined as a birth weight < −2SD
or > +2 SD of the mean weight respectively as calculated by
ultrasound scan compared to the expected value for the
gestational length according to the Swedish growth stand-
ard [21]. Gestational age at delivery estimation was based
on second-trimester ultrasound scan, or if this was not
available then based on last menstrual period. For women
who underwent in vitro fertilization and oocyte donation,
gestational age was also calculated from the date of the em-
bryo transfer. The ultrasound scan which is performed by
specialized personnel during the 16th–19th gestational week
constitutes common practice in Sweden and is attended by
98 % of pregnant women [22].
The medical indications that led to oocyte donation
were also studied. Poor responders were classified accord-
ing to the Bologna criteria [23] i.e. women with high FSH
levels menstrual cycle day 3–5, women with cancelled IVF
treatment due to suboptimal response as well as those
with idiopathic premature ovarian insufficiency. The cat-
egory “egg factor” is generally poorly defined but it is
widely associated to oocyte-related infertility with suffi-
cient quantity of oocytes but somehow defective quality.
Statistical analysis
All statistical analyses were performed using IBM SPSS v.20
(IBM Inc., Armonk, NY, USA). In all analyses, a p-value of
<0.05 (two-sided) was considered statistically significant.
Demographic and clinical characteristics were compared
between Index women and Control group A and B respect-
ively, using Student’s t-test (normally distributed variables)
and Mann-Whitney U test (non-normally distributed vari-
ables) for continuous data and Chi square test for categor-
ical data. Afterwards the association between various
obstetric outcomes and index/control group status was
studied by first comparing oocyte recipients to spontan-
eously pregnant women (Control group A) and then oocyte
recipients to women having conceived with conventional
non-donor IVF (Control group B). The comparisons were
performed with the use of Chi square or Fisher’s exact test
as well as logistic regression analyses; first a single regres-
sion model, i.e. without adjustment for socio-demographic
or birth characteristics and afterwards by composing a
multiple logistic regression model. A number of possible
covariates based on results from previous studies were con-
sidered for inclusion in the multiple logistic regression
model: maternal age as completed years on delivery day
(two categories, <35 years or ≥35 years); body mass index
(BMI, kg/m2) defined as BMI recorded at first antenatal
visit (two categories, <25 kg/m2 or ≥ 25 kg/m2); nicotine
use as either smoking cigarettes or smokeless tobacco
(“snus”) (no/yes) defined as smoker 3 months before con-
ception or at first visit to the prenatal center in gestational
week 10; gestational length (continuous variable); and pres-
ence of chronic medical conditions (no/yes). For the
purpose of comparison, women who conceived spontan-
eously (Control group A) or by conventional IVF (Control
group B) were referred to as having an odds ratio of 1.0.
The odds ratios and corresponding 95 % confidence inter-
vals were calculated.
Sensitivity analysis
According to the literature, nulliparous women have a
higher risk for all adverse outcomes (i.e. nulliparity tri-
ples the risk for preeclampsia [24]). As our study group
consisted of 92.1 % nulliparous (in contrast to 100 % in
Control group A) we performed a sensitivity analysis in
order to assess its possible influence. Parity did not
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appear to influence the obstetric outcomes. Thus, we did
not adjust for parity and we intentionally included mul-
tiparous women in the analysis, even though the risk for
adverse perinatal outcomes is lower, in order not to
compromise sample size, while minimizing any risks for
false associations.
Details of ethics approval
The study was approved by the Regional Ethical Review
Board in Linköping, Sweden (Nr M29–05, T113–07 and
Nr 2012/289–32).
Results
Demographic data and obstetric characteristics concern-
ing oocyte recipients (Index group), Control group A
(spontaneous conception) and Control group B (non
donor IVF) are summarized in Table 1. Although the
median age differed between Index women and Control
Group A, no significant differences were noted after
stratification (initial matching according to study de-
sign). Regarding parity, all 150 women (100 %) in Con-
trol group A were nulliparous, in contrast to 58/63
women (92.1 %) in Control Group B and 70/76 women
(92.1 %) of the Index group (5 multiparous with parity
2–3 and 6 multiparous with parity 2–4 respectively).
The chronic medical conditions reported were asthma,
pre-gestational diabetes mellitus, hypothyroidism, epi-
lepsy, mental health disorders, Crohn’s disease, Systemic
Lupus Erythematosus (SLE), Inflammatory Systemic
Disease, Rheumatoid Arthritis (RA), renal disease (renal
agenesis, renal insufficiency and renal transplantation),
anemia, thrombosis and hematological diseases (data not
shown). It should be noted that the prevalence of these
conditions did not differ between the groups with the
exception of hypothyroidism (7 oocyte recipients vs 1 in
Control Group A and 0 in Control Group B), 40 % of
which could be attributed to women with Turner syn-
drome, possibly due to careful pre-pregnancy screening
of Turner women in Sweden [25]. University clinics are
almost unanimous that women with severe comorbidi-
ties should be declined treatment; thus, only relatively
healthy women were included in the Index group.
Tables 2 and 3 describe obstetric outcomes, either
medical practices or complications, for the Index group
and Control groups A and B. Women who underwent
oocyte donation had overall more pregnancy complica-
tions compared to both Control groups (Tables 2 and 3).
In particular, oligohydramnios was diagnosed more often
among Index group versus Control group A (9.2 % vs
0.7 % respectively) [adjusted OR = 12.74, 95 % CI (1.24–
130.49)]. The overrepresentation of oligohydramnios
among the Index population might in part reflect an
overdiagnosis due to frequent ultrasound scans on this
group. Cesarean section was performed more often
among women who conceived with donated oocytes
(55.3 %) vs pregnant women with autologous oocytes
(26 % in Control group A and 19 % in Control group B).
It should be noted that when compared to Control
Table 1 Demographic and obstetrical data for oocyte recipients (Index group) and Control groups A and B
Index group (n = 76) Control group A (n = 150) Control group B (n = 63)
Median (IQR) Min-Max Median (IQR) Min-Max Median (IQR) Min-Max
Age, years 35.0 (4.0) 25–43 34.0 (4.0)*** 19–36 33.0 (5.0)* 25–39
<35 36(47.4 %) 82(54.7 %) 42(66.7 %)*
≥35 40(52.6 %) 68(45.3 %) 21(33.3 %)*
Median (IQR) Min-Max Median (IQR) Min-Max Median (IQR) Min-Max
Estimated gestational age, week 40.0 (4.0) 28–42 40.0 (3.0) 28–43 39.0 (2.0) 36–42
Mean (SD) Min-Max Mean (SD) Min-Max Mean (SD) Min-Max
BMI, kg/m2 24.98(3.65) 18.0–34.6 24.32 (3.93) 18.1–41.0 24.06(3.54) 16.0–32.6
<25 33(47.1 %) 87(65.9 %)* 40(64.5 %)*
≥25 37(52.9 %) 45(34.1 %)* 22(35.5 %)*
Nulliparity 70/76(92.1 %) 150/150 (100 %) 58/63(92.1 %)
Nicotine use
No 63/68(92.6 %) 110/141(78 %)** 56/61(91.8 %)
Yes 5 /68(7.4 %) 31/141 (22 %)** 5/61 (8.2 %)
Chronic diseases
No 55/76(72.4 %) 131/150(87.3 %)* 54/63(85.7 %)




Elenis et al. BMC Pregnancy and Childbirth  (2015) 15:247 Page 4 of 9
group A, oocyte recipients had a higher risk for non
emergency Cesarean section [aOR 5.13, 95 % CI(2.00–
13.17)], whereas when compared to Control group B
had higher risk for emergency Cesarean Section [aOR
15.98, 95 % CI (3.27–78.23)]. The prevalence of hyper-
tensive disorders of pregnancy in women after oocyte
donation (Index group) was 2.5-fold higher than in pa-
tients with spontaneous conception (Control group A)
(15.8 % versus 6 %; p = 0.017). There were no differences
in prevalence of eclampsia and pregnancy-induced
hypertension. The preeclampsia rates were 13.2 % for
oocyte recipients, whereas only 6 % for women having
conceived spontaneously and 9.5 % for IVF women
(Tables 2 and 3) which are comparable to that of the
general obstetric population in Sweden (2–10 %) [26, 27]. It
should be observed that when gestational hypertensive dis-
orders were analysed independently and not as a unified
group, statistical significance was not reached possibly due
to the relatively small number of cases in each category.
Nevertheless, no associations were found regarding compli-
cations such as pre-gestational and gestational diabetes
mellitus, placenta praevia and placental abruption, SGA or
LGA infant, polyhydramnios and obstetrical lacerations of
3rd or 4th grade (data not shown). Furthermore medical
practices such as use of epidural analgesia or nitrous oxide
use during active labor did not differ between groups.
In Table 4, the distribution of the medical indications
that led to oocyte donation treatment among oocyte re-
cipients is presented. The most common reason for re-
ceiving donated oocytes was premature ovarian failure
or being “poor responder” [23] (48.7 %) followed by
Turner syndrome (13.2 %) and bilateral oophorectomy
or post chemotherapy (11.8 %).
In Table 5, a subgroup analysis within the Index group
based on the indication of treatment and compared to
Control group A is presented. The analysis revealed that
induction of labor and caesarean section occurred more
frequently among the group of women with premature
ovarian insufficiency or who were “poor responders”
(45.9 and 56.8 % respectively) compared to other indica-
tions of OD treatment (41.2 and 50 % respectively) or
spontaneously conceived pregnancies (Table 5). Risk for
Table 2 Unadjusted and adjusted odds ratios (OR) and corresponding 95 % confidence intervals (CI) for delivery related outcomes
for women treated with donated oocytes (Index group) compared to women with no history of infertility (Control group A)
Outcome Index group n/N (%) Control group A, n/N (%) Crude OR (95 % CI) Adjusted OR (95 % CI)
Normal delivery 21/76 (27.6 %)*** 90/150 (60 %) 0.26 (0.14–0.50)* 0.30 (0.15–0.60)**
Instrumental deliverya 13/58 (22.4 %) 20/142 (14.1 %) 1.77 (0.74–4.25) 1.95 (0.75–5.09)
Caesarean Section (CS) 42/76 (55.3 %)*** 39/150 (26 %) 3.69 (1.97–6.92)*** 2.95 (1.52–5.71)**
Non emergency CS 18/76 (23.7 %)*** 8/150 (5.3 %) 5.79 (2.36–14.22)*** 5.13 (2.00–13.17)**
Emergency CSa 24/58(41.4 %)** 31/142(21.8 %) 2.49(1.20–5.13)** 1.93(0.88–4.22)
Induction of labora 33/58 (56.9 %)*** 31/142 (21.8 %) 3.34 (1.63–6.82)*** 3.00 (1.39–6.44)**
Uterine Inertia, primary-secondarya 13/58 (22.4 %) 32/142 (22.5 %) 0.82 (0.36–1.84) 0.88 (0.36–2.16)
Hypertensive disorders of pregnancyf 12/76 (15.8 %)* 9/150 (6 %) 3.42 (1.32–8.86)* 2.84 (1.04–7.81)*
Pregnancy-Induced Hypertension 2/76 (2.6 %) 0/150 – –
Preeclampsia 10/76 (13.2 %) 9/150 (6 %) 2.37 (0.92–6.12) 2.41 (0.84–6.89)
Fetal distressa 16/58 (27.6 %)* 21/142 (14.8 %) 2.62 (1.11–6.19)* 1.96 (0.78–4.97)
Very Preterm birth (<32 weeks) 3/76 (3.9 %) 3/150 (2.0 %) 6.19 (0.63–60.76) 6.48 (0.61–68.56)b
Preterm birth (<37 weeks) 13/76 (17.1 %) 13/150 (8.7 %) 2.42 (0.97–6.05) 1.86 (0.70–4.95)b
Maternal Hospitalization post partum
≥2 days 73/75(97.3 %)** 127/148 (85.8 %) 10.40 (1.36–79.80)* 4.47 (0.53–37.76)c
≥3 days 59/75(78.7 %)** 86/148 (58.1 %) 2.64 (1.33–5.26)** 1.14 (0.51–2.58)c
Post-partum hemorrhage 12/76 (15.8 %)** 7/150 (4.7 %) 3.29 (1.12–9.70)** 7.11(2.02–24.97)d**
Retained placentae 8/34 (23.5 %)** 4/111 (3.6 %) 7.58 (2.03–28.30)** 6.71 (1.58–28.40)*
All outcomes are adjusted for maternal age (<35, ≥35 years), BMI (<25 or ≥25 kg/m2), Nicotine Use (Yes/No), Gestational length (continuous variable, weeks),
Chronic diseases (Yes/No)
aExcluding all non-emergency Caesarean Section (CS)
bNot adjusted for gestational length but for all other covariates
cAdjusted for usual covariates, CS and Hypertensive disorders
dAdjusted for usual covariates and CS
eExcluding all CS
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postpartum hemorrhaging was highest for the subgroup
“other indication” of OD treatment.
Discussion
Our analysis provides evidence that oocyte donation is
associated with hypertensive disorders of pregnancy, oli-
gohydramnios, induction of labor, delivery by caesarean
section, retained placenta, post-partum hemorrhage and
longer hospital stay after delivery even though oocyte re-
cipients in our study are quite healthy and relatively
young. The association between oocyte donation and
hypertensive disorders of pregnancy remained significant
even after adjustment for various covariates.
Although several previous studies investigating obstet-
ric and perinatal pregnancy outcomes after oocyte dona-
tion have been performed, most of them lacked an
appropriate control group; thus the only studies with a
design similar to ours are the ones by Malchau et al. and
Stoop et al. Malchau et al. [8] investigated perinatal out-
comes in 375 pregnancies after oocyte donation in a Da-
nish national cohort study and showed two- to threefold
increased risk regarding hypertensive disorders and cae-
sarean section in OD pregnancies when compared to
IVF/ICSI and spontaneously conceived singleton preg-
nancies. It should however be noted that our study
population, despite being of similar ethnical origin, com-
prises women younger than the women in the Danish
cohort [8], thus strengthening the reported results.
Stoop et al. [7], performed a matched-pair analysis with
Table 3 Unadjusted and adjusted Odds Ratios (OR) and corresponding 95 % confidence intervals (CI) for delivery related outcomes
for women treated with donated oocytes (Index group) compared to women treated with traditional IVF (Control group B)
Outcome Index group n/N(%) Control group B, n/N(%) Crude OR (95 % CI) Adjusted OR (95 % CI)
Normal delivery 21/76(27.6 %)*** 39/63(61.9 %) 0.25 (0.12–0.53)*** 0.29 (0.13–0.65)**
Instrumental deliverya 13/58 (22.4 %) 12/53(22.6 %) 0.90(0.35–2.33) 0.86 (0.29–2.55)
Caesarean Section (CS) 42/76(55.3 %)*** 12/63 (19 %) 6.01 (2.65–13.59)*** 5.20 (2.21–12.22)***
Non emergency CS 18/76 (23.7 %) 10/63(15.9 %) 2.21 (0.91–5.40) 1.82 (0.71–4.66)
Emergency CSa 24/58(41.4 %)*** 2/53 (3.8 %) 16.96 (3.68–78.24)*** 15.98 (3.27–78.23)**
Induction of labora 33/58(56.9 %)*** 12/53(22.6 %) 3.19 (1.35–7.56)*** 2.80 (1.10–7.08)*
Uterine Inertia, primary-secondarya 13/58 (22.4 %)* 4/53 (7.5 %) 3.24 (0.94–11.17) 3.67 (0.92–14.66)
Hypertensive disorders of pregnancyf 12/76 (15.8 %) 6/63 (9.5 %) 2.08 (0.73–5.93) 1.66 (0.54–5.08)
Pregnancy-Induced Hypertension 2/76 (2.6 %) 0 – –
Preeclampsia 10/76 (13.2 %) 6/63 (9.5 %) 1.44 (0.49–4.21) 1.39 (0.44–4.42)
Fetal distressa 16/58 (27.6 %)* 5/53 (9.4 %) 3.22 (1.04–9.99)* 2.86 (0.83–9.86)
Very preterm birth (<32 weeks) 3/76 (3.9 %) 0 – –
Preterm birth (<37 weeks) 13/76 (17.1 %)* 3/63 (4.8 %) 3.94 (1.04–14.88)* 3.45 (0.88–13.62)b
Maternal Hospitalization post partum
≥2 days 73/75 (97.3 %)* 54/63(85.7 %) 10.87 (1.34–90.91)* 5.26 (0.55–50.35)c
≥3 days 59/75(78.7 %)** 35/63(55.6 %) 3.03 (1.39–6.58)** 1.74 (0.70–4.34)c
Post-partum hemorrhage 12/76 (15.8 %) 6/63 (6.5 %) 1.47 (0.49–4.42) 3.67(1.03–13.03) d*
Retained placentae 8/34 (23.5 %) 4/51 (7.8 %) 3.83 (1.01–14.53)* 2.98 (0.73–12.18)
All outcomes are adjusted for maternal age (<35, ≥35 years), BMI (<25 or ≥25 kg/m2), Nicotine Use (Yes/No), Gestational length (continuous variable, weeks),
Chronic diseases (Yes/No)
aExclude all non-emergency Caesarean Section (CS)
bNon adjusted for gestational length but for all other covariates
cAdjusted for usual covariates, CS and Hypertensive disorders
dAdjusted for usual covariates and CS
eExclude all CS




Table 4 Indication to infertility treatment among participating
women in the oocyte donation group
Indication to oocyte donation n Percent (%)
Poor responder & Premature Ovarian Insufficiency (POI) 37 48.7
Turner syndrome 10 13.2
After oophorectomy/chemotherapy 9 11.8
“Egg factor” 6 7.9
Multiple unsuccessful IVF cycles 5 6.6
Genetic reasons 5 6.6
Unclassified 4 5.3
Total 76 100.0
The category “egg factor refers to oocyte-related infertility with sufficient
quantity of oocytes that were somehow defective in quality
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regard to age, ethnicity, parity and plurality between OD
and IVF conceived women with autologous oocytes.
They reported a similar trend towards a higher incidence
of pregnancy-induced hypertension, preterm birth, cae-
sarean section and instrumental delivery in the OD
study group [7]. In contrast to some previous reports,
we did not demonstrate any increased risk for gesta-
tional diabetes among women having conceived through
oocyte donation, possibly due to the lower age and even
perhaps lower weight of our population [28–30].
Caesarean section was performed more often among
oocyte recipients than controls in a national setting
where vaginal delivery (84 % of all singleton deliveries in
Sweden) is the mode of delivery of first choice [31]. It
should, however, be noted that the high proportion of
cesarean section cannot be solely attributed to the obste-
trician’s or woman’s choice since elective (humanitarian)
caesarean section did not differ between the groups
(data not shown). Furthermore, the period during which
they stayed at the hospital after delivery (≥3 days) was
longer in the study group but the risk was eliminated
after adjusting for the presence of hypertensive disor-
ders, caesarean section and the usual covariates. Trends
were also noted regarding preterm birth and very pre-
term birth but the overall gestational length did not dif-
fer between the groups. High risk for post partum
hemorrhage was observed even after adjusting for opera-
tive delivery with greater prevalence than expected by
previous reports [25, 32].
Finally, after investigating adverse obstetric outcomes
with regard to the indication of OD treatment, a ten-
dency towards greater maternal complications was ob-
served for women with declining ovarian reserve. This is
partly in accordance with the findings of Keegan et al.
[33] and Pados et al. [34] who demonstrated that young
oocyte recipients exhibited the highest rates of gesta-
tional hypertension and preeclampsia, which indicates a
possible relationship between diminished ovarian func-
tion and hypertensive disorders. However, caution is ad-
vised in the interpretation of the data due to the limited
size of the study population, as seen by the wide confi-
dence interval.
Strengths and limitations of the study
The major strength of our study is its national design
comprising all centers allowed to perform IVF treatment
with donated oocytes in Sweden and hence recruiting a
wide range of women from both urban and rural areas.
Furthermore it is one of the few that compares three
modes of conception [6, 8] and constitutes one of the lar-
gest series on singletons pregnancies after oocyte donation
published thus far, with a well defined and age matched
control group [7, 8] where the medical indication of the
oocyte donation treatment for every woman was taken
into account. In addition, in Sweden, antenatal care is
standardized and free of charge with good availability of
the public health system independently of social or em-
ployment status and educational level of the pregnant
woman. Thus, the differences noted on the various out-
comes cannot be vastly attributed to different level of ob-
stetric care given. Finally, our study group comprises
relatively young recipient women with ascertained health
status with donated oocytes derived from young (≤35 years)
fertile women and not through egg sharing from other in-
fertile women undergoing ART. It should be stressed that
the participating clinics at the nationwide oocyte donation
program, despite not having a standardized way of making
the evaluation of the recipients but rather following their
own clinical policy, seem nevertheless to be unanimous
Table 5 Unadjusted and adjusted Odds Ratios (OR) and corresponding 95 % confidence intervals (CI) for delivery related
complications for women treated with donated oocytes compared to women who conceived spontaneously (Control group A),
reported by cause for oocyte donation
Oocyte recipients othera Oocyte recipients POIb
Crude OR (95 % CI) Adjusted OR (95 % CI) Crude OR (95 % CI) Adjusted OR (95 % CI)
Hypertensive disorders 4.13(1.30–13.05)* 3.13 (0.94–10.48) 3.49(1.12–10.92)* 3.42 (0.99–11.87)
Induction of labourc 2.53 (0.93–6.93)** 2.59 (0.88–7.65) 4.11(1.66–10.22)** 3.33 (1.25–8.82)*
Cesarean section 2.79 (1.21–6.46)* 2.35 (0.98–5.62) 4.08 (1.82–9.15)** 3.03 (1.28–7.15)*
Post-partum hemorrhage 3.42 (0.90–13.03) 7.04 (1.45–34.16)*d 2.93 (0.78–11.07) 5.97(1.11–32.15)*d
Uterine inertiac 0.36 (0.08–1.64) 0.42 (0.09–2.07) 1.01 (0.37–2.78) 0.93 (0.30–2.84)
aWomen with Turner syndrome, oophorectomy/chemotherapy, “egg factor”, multiple unsuccessful IVF cycles, genetic reasons, unclassified
bPOI: Premature ovarian insufficiency and poor responders
All outcomes are adjusted for maternal age (<35, ≥35 years), BMI (<25 or ≥25 kg/m2), Nicotine Use (No/Yes), Gestational length (continuous variable, weeks),
Chronic diseases (No/Yes)
cExclude all non-emergency CS
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regarding the importance of relatively young age and good
health status of the oocyte recipients.
One of the limitations of our study is the lack of
power, as shown by the wide confidence intervals, which
may limit the interpretation of some results. Moreover,
due to the retrospective design of our study and because
infertility is often unreported in obstetric records, we
cannot exclude the possibility that there might be
women with a history of infertility in Control group A.
On the other hand, this fact would only lead to under-
estimation of associations. Finally in the assessment of
the various outcomes, we did not take into account pa-
rameters such as donor age, paternal age, ART method
(conventional IVF or ICSI) as well as if the pregnancy
resulted from a cryopreserved or fresh embryo. It should
however be noted that large series did not find donor
age to have a significant association with perinatal out-
come [7, 35]; this according to the authors might in part
reflect the homogeneity of the oocyte donor population
i.e. more than 98 % of donors reported being younger
than 35 years. Similar conditions apply even in Sweden
where according to common practice in the various IVF
university clinics the vast majority of donors are an-
onymous, younger than 35 years and with proven fertil-
ity. In particular, the nationwide study on oocyte
donation in Sweden reported a mean age of 31.5 ±
4.6 years for oocyte donors supporting the conclusions
deducted [36].
Conclusion
Our study confirms that the evaluation process of oocyte
recipients in Sweden appears to be successful in exclud-
ing women with severe comorbidities. However, oocyte
recipients based on medical indication, despite being of
young age and optimal health, have higher risks for ad-
verse obstetric outcomes compared to women conceiving
with autologous oocytes, regardless of mode of concep-
tion. Obstetricians should therefore provide careful coun-
seling preconceptionally and closer monitoring prenatally
regarding the development of hypertensive disorders.
Abbreviations
ART: Assisted reproductive technology; CS: Caesarean section; IVF: In vitro
fertilization; LGA: Large for Gestational Age; MBR: Medical Birth Register;
OD: Oocyte Donation; SGA: Small for Gestational Age.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
EE participated in the design of the study, performed the statistical analysis
and prepared the manuscript. CL assisted in data collection and drafted the
manuscript. GS and ASS conceived of the study, supervised the analysis and
writing of the manuscript. HÅ and AS assisted substantially in the statistical
analysis and drafted the manuscript. All authors read and approved the final
version of the manuscript.
Acknowledgements
We would like to thank the statistician Marie Bladh for her contribution in
acquisition of the data and in statistical analysis, as well as the personnel at
the fertility clinics at the University Hospitals in Stockholm, Gothenburg,
Uppsala, Linköping, Malmö, Örebro and Umeå who made great contributions
to the recruitment of participants and data collection. Merck Serono provided
support during the implementation of the study. Grants were received from
the Family Planning Fond in Uppsala and Swedish Research Council for Health,
Working Life and Welfare.
Author details
1Department of Women’s and Children’s Health, Uppsala University, Uppsala
University Hospital, Uppsala SE-751 83, Sweden. 2Department of
Neurobiology, Care sciences and Society, Karolinska Institutet, Solna, Sweden.
3Obstetrics and Gynaecology, Department of Clinical Experimental Medicine,
Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Received: 20 April 2015 Accepted: 4 October 2015
References
1. Soderstrom-Anttila V, Hovatta O. Oocyte donation to be legalized in
Sweden. Excellent results reported from other countries. Lakartidningen.
2002;99:3118–21. Aggdonation blir lagligt i Sverige. Goda erfarenheter
uppvisas fran andra lander.
2. Sheffer-Mimouni G, Mashiach S, Dor J, Levran D, Seidman DS. Factors
influencing the obstetric and perinatal outcome after oocyte donation.
Hum Reprod. 2002;17:2636–40.
3. Wiggins DA, Main E. Outcomes of pregnancies achieved by donor egg
in vitro fertilization–a comparison with standard in vitro fertilization
pregnancies. Am J Obstet Gynecol. 2005;192:2002–6. discussion 6-8.
4. Porreco RP, Harden L, Gambotto M, Shapiro H. Expectation of pregnancy
outcome among mature women. Am J Obstet Gynecol. 2005;192:38–41.
5. Pecks U, Maass N, Neulen J. Oocyte donation: a risk factor for pregnancy-
induced hypertension: a meta-analysis and case series. Dtsch Arztebl Int.
2011;108:23–31.
6. Le Ray C, Scherier S, Anselem O, Marszalek A, Tsatsaris V, Cabrol D, et al.
Association between oocyte donation and maternal and perinatal
outcomes in women aged 43 years or older. Hum Reprod. 2012;27:896–901.
7. Stoop D, Baumgarten M, Haentjens P, Polyzos NP, De Vos M, Verheyen G,
et al. Obstetric outcome in donor oocyte pregnancies: a matched-pair
analysis. Reprod Biol Endocrinol. 2012;10:42.
8. Malchau SS, Loft A, Larsen EC, Aaris Henningsen AK, Rasmussen S,
Andersen AN, et al. Perinatal outcomes in 375 children born after oocyte
donation: a Danish national cohort study. Fertil Steril. 2013;99:1637–43.
9. Wolff KM, McMahon MJ, Kuller JA, Walmer DK, Meyer WR. Advanced
maternal age and perinatal outcome: oocyte recipiency versus natural
conception. Obstet Gynecol. 1997;89:519–23.
10. Gundogan F, Bianchi DW, Scherjon SA, Roberts DJ. Placental pathology in
egg donor pregnancies. Fertil Steril. 2010;93:397–404.
11. van der Hoorn ML, Scherjon SA, Claas FH. Egg donation pregnancy as an
immunological model for solid organ transplantation. Transpl Immunol.
2011;25:89–95.
12. Soares SR, Troncoso C, Bosch E, Serra V, Simon C, Remohi J, et al. Age and
uterine receptiveness: predicting the outcome of oocyte donation cycles.
J Clin Endocrinol Metab. 2005;90:4399–404.
13. Q-IVF. TNQRoAR. Sweden; 2014. Available from: http://www.ucr.uu.se/qivf/
index.php/behandlingsresultat.
14. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D’Hooghe T, Castilla JA,
et al. Assisted reproductive technology in Europe, 2010: results
generated from European registers by ESHREdagger. Hum Reprod.
2014;29:2099–113.
15. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D’Hooghe T, Castilla JA, et al.
Assisted reproductive technology in Europe, 2010: results generated from
European registers by ESHREdagger. Hum Reprod. 2014;29:S1–33.
16. Sydsjo G, Lampic C, Bladh M, Skoog SA. Relationships in oocyte recipient
couples - a Swedish national prospective follow-up study. Reprod Health.
2014;11:38.
17. Cnattingius S, Ericson A, Gunnarskog J, Kallen B. A quality study of a
medical birth registry. Scand J Soc Med. 1990;18:143–8.
Elenis et al. BMC Pregnancy and Childbirth  (2015) 15:247 Page 8 of 9
18. Quaranta M, Erez O, Mastrolia SA, Koifman A, Leron E, Eshkoli T, et al.
The physiologic and therapeutic role of heparin in implantation and
placentation. PeerJ. 2015;3:e691.
19. Welfare NBoHa. The Swedish Medical Birth Register: a summary of content
and quality. 2003. Available from: http://www.socialstyrelsen.se/
publikationer2003/2003-112-3.
20. Marino JL, Moore VM, Willson KJ, Rumbold A, Whitrow MJ, Giles LC, et al.
Perinatal outcomes by mode of assisted conception and sub-fertility in an
Australian data linkage cohort. PLoS One. 2014;9:e80398.
21. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine
growth curves based on ultrasonically estimated foetal weights. Acta
Paediatr. 1996;85:843–8.
22. Graviditetsregistret. Årsrapport 2013 2014 07/09/2015. Available from:
https://www.medscinet.com/GR/app/Uploads/hemsida/
GR_%C3%85rsrapport-2013_20141113.pdf.
23. Ferraretti AP, Goossens V, de Mouzon J, Bhattacharya S, Castilla JA, Korsak V,
et al. Assisted reproductive technology in Europe, 2008: results generated
from European registers by ESHRE. Hum Reprod. 2012;27:2571–84.
24. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking:
systematic review of controlled studies. BMJ. 2005;330:565.
25. Hagman A, Loft A, Wennerholm UB, Pinborg A, Bergh C, Aittomaki K, et al.
Obstetric and neonatal outcome after oocyte donation in 106 women with
Turner syndrome: a Nordic cohort study. Hum Reprod. 2013;28:1598–609.
26. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia
and gestational hypertension in a population-based cohort study. Am J
Epidemiol. 1998;147:1062–70.
27. Kallen B, Finnstrom O, Nygren KG, Otterblad Olausson P, Wennerholm UB. In
vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity
and mortality. BJOG. 2005;112:1529–35.
28. Koo YJ, Ryu HM, Yang JH, Lim JH, Lee JE, Kim MY, et al. Pregnancy outcomes
according to increasing maternal age. Taiwan J Obstet Gynecol. 2012;51:60–5.
29. Cleary-Goldman J, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH,
et al. Impact of maternal age on obstetric outcome. Obstet Gynecol.
2005;105:983–90.
30. Joseph KS, Allen AC, Dodds L, Turner LA, Scott H, Liston R. The perinatal
effects of delayed childbearing. Obstet Gynecol. 2005;105:1410–8.
31. Welfare NBoHa. Pregnancies, deliveries and newborn infants. The Swedish
Medical Birth Register 1973-2012. Assisted Reproduction Treatment 1991-
2011. Stockholm; 2013. Available from: https://www.socialstyrelsen.se/Lists/
Artikelkatalog/Attachments/19289/2013-12-16.pdf.
32. Abdalla HI, Billett A, Kan AK, Baig S, Wren M, Korea L, et al. Obstetric outcome
in 232 ovum donation pregnancies. Br J Obstet Gynaecol. 1998;105:332–7.
33. Keegan DA, Krey LC, Chang HC, Noyes N. Increased risk of pregnancy-
induced hypertension in young recipients of donated oocytes. Fertil Steril.
2007;87:776–81.
34. Pados G, Camus M, Van Steirteghem A, Bonduelle M, Devroey P. The
evolution and outcome of pregnancies from oocyte donation. Hum Reprod.
1994;9:538–42.
35. Kawwass JF, Monsour M, Crawford S, Kissin DM, Session DR, Kulkarni AD,
et al. Trends and outcomes for donor oocyte cycles in the United States,
2000-2010. JAMA. 2013;310:2426–34.
36. Sydsjo G, Lampic C, Brandstrom S, Gudmundsson J, Karlstrom PO, Solensten
NG, et al. Personality characteristics in a Swedish national sample of
identifiable oocyte donors. BJOG. 2011;118:1067–72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Elenis et al. BMC Pregnancy and Childbirth  (2015) 15:247 Page 9 of 9
